South Africa Receives First Batch of New HIV Prevention Injection
The Department of Health has confirmed the arrival of South Africa’s first shipment of Lenacapavir, marking a significant development in efforts to curb new HIV infections.
Approximately 38,000 doses of the long-acting injectable have been delivered, introducing a new prevention option in the country’s HIV response.
BOOST FOR HIV PREVENTION EFFORTS
Health authorities say the medication could play a key role in reducing infection rates, particularly among individuals who face challenges with existing prevention methods.
The rollout supports South Africa’s broader goal of ending AIDS as a public health threat by 2030.
LONG-ACTING INJECTION OFFERS CONVENIENCE
Lenacapavir is administered twice a year, making it a more convenient alternative for many users.
It is expected to improve adherence, especially among high-risk groups such as young women, sex workers and men who have sex with men.
NATIONAL ROLLOUT TO FOLLOW
The department has indicated that further details on the official launch and phased rollout plan will be announced soon.
Officials have described the treatment as a major advancement in HIV prevention, noting that it is a preventive option rather than a vaccine.